

# Kristen L Nowak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2090546/publications.pdf>

Version: 2024-02-01

61  
papers

3,414  
citations

249298

26  
h-index

169272

56  
g-index

61  
all docs

61  
docs citations

61  
times ranked

6082  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. American Journal of Kidney Diseases, 2022, 79, 518-526.	2.1	26
2	PKD1 Compared With PKD2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies. Kidney International Reports, 2022, 7, 117-120.	0.4	1
3	Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. IScience, 2022, 25, 103697.	1.9	16
4	Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 240-250.	2.2	8
5	Association of Monocyte Count and Monocyte/Lymphocyte Ratio with the Risk of Cardiovascular Outcomes in Patients with CKD. Kidney360, 2022, 3, 657-665.	0.9	5
6	Overweight and Obesity and Progression of ADPKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 908-915.	2.2	30
7	Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies. Kidney Medicine, 2021, 3, 536-545.e1.	1.0	11
8	Arterial Stiffness Is Independently Associated with Acute Kidney Injury in SPRINT. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, CJN.06420521.	2.2	0
9	A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360, 2021, 2, 224-235.	0.9	1
10	Management of Mineral and Bone Disorders in Chronic Kidney Disease. , 2020, , 1013-1033.		1
11	Apoptosis and autophagy in polycystic kidney disease (PKD). Cellular Signalling, 2020, 68, 109518.	1.7	39
12	Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: Design and baseline characteristics of participants. Contemporary Clinical Trials Communications, 2020, 19, 100635.	0.5	13
13	Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. Kidney360, 2020, 1, 648-656.	0.9	4
14	Vascular Dysfunction, Oxidative Stress, and Inflammation in Chronic Kidney Disease. Kidney360, 2020, 1, 501-509.	0.9	8
15	Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 577-584.	2.2	65
16	Dietary Sodium Restriction Decreases Urinary Ngal in Older Adults with Moderately Elevated Systolic Blood Pressure Free from Chronic Kidney Disease. Journal of Investigative Medicine, 2020, 68, 1271-1275.	0.7	2
17	Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients. Kidney International Reports, 2019, 4, 1742-1748.	0.4	5
18	IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 702-711.	2.2	22

#	ARTICLE	IF	CITATIONS
19	Serum Sodium and Pulse Pressure in SPRINT. American Journal of Hypertension, 2019, 32, 649-656.	1.0	5
20	Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2019, 74, 213-223.	2.1	13
21	Does inflammation affect outcomes in dialysis patients?. Seminars in Dialysis, 2018, 31, 388-397.	0.7	55
22	Serum Sodium and Cognition in Older Community-Dwelling Men. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 366-374.	2.2	30
23	Dietary Sodium/Potassium Intake Does Not Affect Cognitive Function or Brain Imaging Indices. American Journal of Nephrology, 2018, 47, 57-65.	1.4	21
24	Strategies for Achieving Healthy Vascular Aging. Hypertension, 2018, 71, 389-402.	1.3	106
25	Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2018, 29, 571-578.	3.0	101
26	Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1463-1470.	2.2	47
27	Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1493-1501.	2.2	40
28	Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial. PLoS ONE, 2018, 13, e0205831.	1.1	13
29	Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study. Clinical Nephrology, 2018, 89, 196-204.	0.4	4
30	Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2017, 32, 342-347.	0.4	36
31	A guiding map for inflammation. Nature Immunology, 2017, 18, 826-831.	7.0	506
32	Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1438-1446.	2.2	38
33	Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults. Journal of the American Society of Nephrology: JASN, 2017, 28, 1239-1246.	3.0	26
34	IL-1 Inhibition and Vascular Function in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 971-980.	3.0	66
35	Vascular Function and Uric Acid-Lowering in Stage 3 CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 943-952.	3.0	56
36	Interleukin-1 inhibition, chronic kidney disease-mineral and bone disorder, and physical function. Clinical Nephrology, 2017, 88, 132-143.	0.4	11

#	ARTICLE	IF	CITATIONS
37	Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2016, 44, 171-178.	1.4	28
38	Mineral Metabolites, Angiotensin II Inhibition and Outcomes in Advanced Chronic Kidney Disease. American Journal of Nephrology, 2015, 42, 361-368.	1.4	8
39	Posthemodialysis Weights and Mortality. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 729-731.	2.2	0
40	Effect of Dietary Sodium Restriction on Human Urinary Metabolomic Profiles. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1227-1234.	2.2	18
41	Vitamin D Level and Risk of Community-Acquired Pneumonia and Sepsis. Nutrients, 2014, 6, 2196-2205.	1.7	45
42	Renal outcomes and dietary potassium: the overshadowed electrolyte?. Kidney International, 2014, 86, 1077-1078.	2.6	4
43	Assessment of Vascular Function in Patients With Chronic Kidney Disease. Journal of Visualized Experiments, 2014, , .	0.2	16
44	25-vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: a veteran population. Clinical Nephrology, 2014, 82 (2014), 296-303.	0.4	15
45	Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 792-798.	1.1	59
46	Dietary Sodium Restriction Reverses Vascular Endothelial Dysfunction in Middle-Aged/Older Adults With Moderately Elevated Systolic Blood Pressure. Journal of the American College of Cardiology, 2013, 61, 335-343.	1.2	126
47	Cystatin-C-based eGFR: what is it telling us?. Nature Reviews Nephrology, 2013, 9, 318-319.	4.1	3
48	Regular aerobic exercise protects against impaired fasting plasma glucose-associated vascular endothelial dysfunction with aging. Clinical Science, 2013, 124, 325-331.	1.8	42
49	Dietary Sodium Restriction and Association with Urinary Marinobufagenin, Blood Pressure, and Aortic Stiffness. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1952-1959.	2.2	63
50	Vascular calcification in end-stage renal disease. Hemodialysis International, 2013, 17, S17-21.	0.4	78
51	Vascular endothelial function is not related to serum uric acid in healthy adults. American Journal of Hypertension, 2012, 25, 407-413.	1.0	17
52	Should statin therapy be expanded in patients with CKD?. Nature Reviews Nephrology, 2012, 8, 440-441.	4.1	1
53	Frequent Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 707-710.	2.2	0
54	Tetrahydrobiopterin Supplementation Enhances Carotid Artery Compliance in Healthy Older Men: A Pilot Study. American Journal of Hypertension, 2012, 25, 1050-1054.	1.0	22

#	ARTICLE	IF	CITATIONS
55	25-Hydroxyvitamin D Deficiency Is Associated With Inflammation-Linked Vascular Endothelial Dysfunction in Middle-Aged and Older Adults. <i>Hypertension</i> , 2011, 57, 63-69.	1.3	301
56	Aging and vascular endothelial function in humans. <i>Clinical Science</i> , 2011, 120, 357-375.	1.8	531
57	Low dietary sodium intake is associated with enhanced vascular endothelial function in middle-aged and older adults with elevated systolic blood pressure. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2009, 3, 347-356.	1.0	44
58	Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 297, H425-H432.	1.5	250
59	Aging is associated with greater nuclear NF $\kappa$ B, reduced I $\kappa$ B $\pm$ , and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. <i>Aging Cell</i> , 2008, 7, 805-812.	3.0	213
60	Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans. <i>Journal of Applied Physiology</i> , 2008, 105, 1359-1363.	1.2	23
61	High-dose ascorbic acid infusion abolishes chronic vasoconstriction and restores resting leg blood flow in healthy older men. <i>Journal of Applied Physiology</i> , 2007, 103, 1715-1721.	1.2	76